EXEL News and Press, Exelixis Inc. From 06/21/22

Exelixis (NASDAQ:EXEL) said it began a phase 3 trial of XL092 in combination with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Tecentriq (atezolizumab) versus Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Stivarga (regorafenib) in patients with metastatic colorectal cancer which is not microsatellite insta...

– STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor – Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination wi...

Exelixis (NASDAQ:EXEL) and Sweden's BioInvent International (OTC:BOVNF) signed a license agreement to develop novel antibodies for use in immuno-oncology therapies. The collaboration will use BioInvent's proprietary n-CoDeR antibody library and patient-centric F.I.R.S.T screening pl...

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent’s proprietary immuno-oncology (IO) screening platform and antibody library - Exelixis...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June: William Blair 42 ...

– Cabozantinib in combination with atezolizumab demonstrated encouraging activity with a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and patients with previously treated advanced non-small cell lung cancer – ...

– Results demonstrated an objective response rate of 54% and an overall clinical benefit rate of 91% – Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX ® ) in combination ...

The most successful investors don't limit their thinking to the here and now. They instead look to the future. That long-term mindset can make the difference between meager gains and monumental profits. We asked three Motley Fool contributors to identify stocks that could make you a for...

Update 1:08pm Updates shares, adds Suntrust analyst comment. Exelixis (NASDAQ:EXEL) plunged 11% during day four of the  Cabometyx patent trial. The judge in the case appeared to telegraph that he will find that the 776 patent, which goes to October 2030, won't be infringed so MSN wi...

Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%. BIT Mining (BTCM) +18%. Losers: Companhia Energetica de Minas G...